MX2022011041A - Tratamiento de dolor y vasoconstriccion. - Google Patents

Tratamiento de dolor y vasoconstriccion.

Info

Publication number
MX2022011041A
MX2022011041A MX2022011041A MX2022011041A MX2022011041A MX 2022011041 A MX2022011041 A MX 2022011041A MX 2022011041 A MX2022011041 A MX 2022011041A MX 2022011041 A MX2022011041 A MX 2022011041A MX 2022011041 A MX2022011041 A MX 2022011041A
Authority
MX
Mexico
Prior art keywords
vasoconstriction
pain
treatment
type
calcium channel
Prior art date
Application number
MX2022011041A
Other languages
English (en)
Inventor
Andrew Sternlicht
Original Assignee
Aisa Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aisa Pharma Inc filed Critical Aisa Pharma Inc
Publication of MX2022011041A publication Critical patent/MX2022011041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describen en la presente métodos para tratar enfermedades y trastornos usando (i) bloqueador de canal de calcio tipo N y tipo L dobles selectivos para el canal de calcio tipo N y/o (ii) bloqueadores de canal de sodio Nav 1.7, incluida cilnidipina.
MX2022011041A 2020-03-06 2021-03-05 Tratamiento de dolor y vasoconstriccion. MX2022011041A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986544P 2020-03-06 2020-03-06
US202063013468P 2020-04-21 2020-04-21
PCT/US2021/021218 WO2021178903A1 (en) 2020-03-06 2021-03-05 Treatment of pain and vasoconstriction

Publications (1)

Publication Number Publication Date
MX2022011041A true MX2022011041A (es) 2022-12-02

Family

ID=75267628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011041A MX2022011041A (es) 2020-03-06 2021-03-05 Tratamiento de dolor y vasoconstriccion.

Country Status (6)

Country Link
US (1) US20230115611A1 (es)
EP (1) EP4114466A1 (es)
AU (1) AU2021231064A1 (es)
CA (1) CA3174618A1 (es)
MX (1) MX2022011041A (es)
WO (1) WO2021178903A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4251164A2 (en) 2020-11-25 2023-10-04 Aisa Pharma, Inc. Treatment of raynaud's disease
WO2023150336A1 (en) * 2022-02-07 2023-08-10 Aisa Pharma, Inc. Methods of treating complex regional pain syndrome

Also Published As

Publication number Publication date
AU2021231064A1 (en) 2022-09-22
CA3174618A1 (en) 2021-09-10
WO2021178903A1 (en) 2021-09-10
EP4114466A1 (en) 2023-01-11
US20230115611A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
MX2022011041A (es) Tratamiento de dolor y vasoconstriccion.
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
MX2023001741A (es) Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.
WO2020163823A8 (en) Therapeutic agents and methods of treatment
MX2022012285A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022011888A (es) Tratamiento de trastornos respiratorios.
MX2023007420A (es) Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
PH12020551527A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
EA202193211A1 (ru) Лечение синуклеопатий
EA202190751A1 (ru) Способы лечения миелопролиферативных расстройств
EA202193276A1 (ru) Способы лечения холангиокарциномы
WO2022115576A3 (en) Treatment of raynaud's disease